ChemoCentryx Inc (CCXI):企業の財務・戦略的SWOT分析

◆英語タイトル:ChemoCentryx Inc (CCXI) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15025
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD300 ⇒換算¥44,400見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ChemoCentryx Inc (ChemoCentryx) is a biopharmaceutical company that discovers, develops and commercializes orally-administered therapeutics for the treatment of cancer, autoimmune diseases, and inflammatory disorders. The company’s lead drug candidate include Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; CCX872, an orally administered inhibitor for pancreatic cancer; and CCX140, an orally-administered inhibitor of the chemokine receptor known for patients with diabetic nephropathy, among others. It also carries out preclinical research for evaluating the effect of combination therapy with chemokine receptor and check point inhibitors. ChemoCentryx is headquartered in Mountain View, California, the US.

ChemoCentryx Inc Key Recent Developments

Jan 24,2019: ChemoCentryx Announces Withdrawal of Phase IIBased Conditional Marketing Authorisation CMA Application for ANCAAssociated Vasculitis in Europe Phase III Advocate Trial Data Release Planned for Q4 2019
Oct 25,2018: Presentations at ASN Kidney Week 2018 Highlight ChemoCentryx Platform in Treatment of ANCA-Associated Vasculitis and Focal Segmental Glomerulosclerosis (FSGS)
Aug 09,2018: Chemocentryx reports second quarter 2018 financial results and recent highlights
May 09,2018: ChemoCentryx Reports First Quarter 2018 Financial Results and Recent Highlights
Mar 09,2018: ChemoCentryx Reports Fourth Quarter And Full Year 2017 Financial Results And Recent Highlights

This comprehensive SWOT profile of ChemoCentryx Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of ChemoCentryx Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

ChemoCentryx Inc – Key Information
ChemoCentryx Inc – Overview
ChemoCentryx Inc – Key Employees
ChemoCentryx Inc – Key Employee Biographies
ChemoCentryx Inc – Key Operational Heads
ChemoCentryx Inc – Major Products and Services
ChemoCentryx Inc – History
ChemoCentryx Inc – Company Statement
ChemoCentryx Inc – Locations And Subsidiaries
ChemoCentryx Inc – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

ChemoCentryx Inc – Business Description
ChemoCentryx Inc – Corporate Strategy
ChemoCentryx Inc – SWOT Analysis
SWOT Analysis – Overview
ChemoCentryx Inc – Strengths
ChemoCentryx Inc – Weaknesses
ChemoCentryx Inc – Opportunities
ChemoCentryx Inc – Threats
ChemoCentryx Inc – Key Competitors

Section 3 – Company Financial Performance Charts

ChemoCentryx Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

ChemoCentryx Inc, Key Information
ChemoCentryx Inc, Key Ratios
ChemoCentryx Inc, Share Data
ChemoCentryx Inc, Major Products and Services
ChemoCentryx Inc, History
ChemoCentryx Inc, Key Employees
ChemoCentryx Inc, Key Employee Biographies
ChemoCentryx Inc, Key Operational Heads
ChemoCentryx Inc, Other Locations
ChemoCentryx Inc, Subsidiaries
ChemoCentryx Inc, Key Manufacturing facilities
ChemoCentryx Inc, Key Competitors
ChemoCentryx Inc, SWOT Analysis
ChemoCentryx Inc, Ratios based on current share price
ChemoCentryx Inc, Annual Ratios
ChemoCentryx Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

ChemoCentryx Inc, Performance Chart
ChemoCentryx Inc, Ratio Charts

★海外企業調査レポート[ChemoCentryx Inc (CCXI):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Senetas Corporation Limited:企業の戦略・SWOT・財務分析
    Senetas Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Senetas Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • CardioGenics Inc:企業の製品パイプライン分析2018
    Summary CardioGenics Inc (CardioGenics), a subsidiary of CardioGenics Holdings Inc is a medical device company that manufactures sensitive diagnostic test products to the in-vitro diagnostics market. The company’s products include QL care analyzer, immunoassay tests, and paramagnetic beads, among ot …
  • CiCi Enterprises, LP:企業の戦略・SWOT・財務情報
    CiCi Enterprises, LP - Strategy, SWOT and Corporate Finance Report Summary CiCi Enterprises, LP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Merz Pharma GmbH & Co. KGaA:企業のM&A・事業提携・投資動向
    Merz Pharma GmbH & Co. KGaA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Merz Pharma GmbH & Co. KGaA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Ampio Pharmaceuticals Inc (AMPE):企業の財務・戦略的SWOT分析
    Summary Ampio Pharmaceuticals Inc (Ampio), formerly Chay Enterprises Inc is a biopharmaceutical company that discovers and develops novel therapeutic candidates for inflammatory conditions. The company develops compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by …
  • Aquestive Therapeutics Inc (AQST):製薬・医療:M&Aディール及び事業提携情報
    Summary Aquestive Therapeutics Inc (Aquestive Therapeutics) is a pharmaceutical company that discovers, develops and commercializes prescription drug products and a pipeline of prescription formulations. The company offers PharmFilm a drug delivery platform that delivers existing prescription produc …
  • Spectrum Health System:企業の戦略的SWOT分析
    Spectrum Health System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Canada Life Financial Corporation:戦略・SWOT・企業財務分析
    Canada Life Financial Corporation - Strategy, SWOT and Corporate Finance Report Summary Canada Life Financial Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Cerner Corp (CERN):医療機器:M&Aディール及び事業提携情報
    Summary Cerner Corp (Cerner) is a provider of healthcare information technology and related services. It offers a comprehensive range of solutions and services which assist the clinical, financial and operational needs of organizations. The company’s major solutions include extended care solutions; …
  • Ego Pharmaceuticals Pty Ltd:企業の戦略的SWOT分析
    Ego Pharmaceuticals Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Alcoa Inc:戦略・SWOT・企業財務分析
    Alcoa Inc - Strategy, SWOT and Corporate Finance Report Summary Alcoa Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • NextEra Energy Inc (NEE)-エネルギー分野:企業M&A・提携分析
    Summary NextEra Energy, Inc. (NEE), formerly FPL Group, Inc., is an energy company that generates, transmits and distributes electricity together with its subsidiaries. The company generates power through various sources such as nuclear, coal, oil and natural gas-fired facilities, and hydro power pl …
  • Great Eastern Holdings Limited (G07):企業の財務・戦略的SWOT分析
    Great Eastern Holdings Limited (G07) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • SmarTone Mobile Communications Ltd:企業の戦略的SWOT分析
    SmarTone Mobile Communications Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Global Petroleum Ltd (GBP):企業の財務・戦略的SWOT分析
    Summary Global Petroleum Ltd (Global Petroleum) is an oil and gas company that offers oil and gas exploration and development services. It operates through a portfolio of oil and gas projects in offshore Namibia and others. Its Namibian Project is into petroleum and gas exploration and Juan de Nova …
  • ROHM Co Ltd (6963):企業の財務・戦略的SWOT分析
    ROHM Co Ltd (6963) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • EOG Resources Inc (EOG):石油・ガス:M&Aディール及び事業提携情報
    Summary EOG Resources Inc (EOG) is an independent upstream oil and gas company. The company, along with its subsidiaries, explores for, develops and produces crude oil and natural gas. EOG has operations in the US, Canada, Trinidad, the UK and China. Its holds licenses for assets in in Eagle Ford, B …
  • HSE Integrated Ltd:企業の戦略的SWOT分析
    HSE Integrated Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Quickstep Holdings Limited:企業の戦略・SWOT・財務情報
    Quickstep Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Quickstep Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Molex LLC-医療機器分野:企業M&A・提携分析
    Summary Molex LLC (Molex), a subsidiary of Koch Industries, is a US-based manufacturer of electronic components. The company principally focuses on manufacturing and sale of electronic, electrical and fiber optic interconnection systems. Molex's product portfolio includes switches, integrated produc …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆